Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 12. Percentages of Patients Reporting Adverse Events by Treatment, Dose, and Gradea

Adverse event Gefitinib single-agent Gefitinib combined with
chemotherapy
Erlotinibb Cytotoxic
chemotherapyc
500 mg/day 250 mg/day 500 mg/day 250 mg/day 150 mg/day
Gr
1-2
Gr
3-4
Gr
1-2
Gr
3-4
Gr
1-2
Gr
3-4
Gr
1-2
Gr
3-4
Gr
1-2
Gr
3-4
Gr
1-2
Gr
3-4
Skin
Rash 62-70 5-7 46-60 0-2 44-62 12-13 41-56 3-4 65-67 2-9 5-13 1
Acne 12 2 13 0 22 5 20 1 - - - - - - - -
Pruritus 35 1 30 0 11-18 2 8-14 0-1 32 4 - - - -
Digestive
Diarrhea 51-70 5-7 8-56 0-6 39-44 12-25 25-48 4-10 49-54 1-6 21-34 2-4
Anorexia 18 1 6-10 0-4 5-11 1-2 5-6 1 20 4 - - - -
Nausea/vomiting - - - - 19 2-9 - - - - - - - - 22 3 - - - -
Nausea - - - - 3-22 0-1 15 4 15-17 2-3 25 0 15-32 2-6
Vomiting 20 - - 6-13 - - 10-12 3-5 10-11 2-3 20 0 11-25 1-7
Stomatitis - - - - - - - - - - - - - - - - 16 <1-2 16-34 1-4
Hematologic
Anemia - - - - 9-12 2 3-6 1-3 2-6 1-2 - - - - - - 4-16
Neutropenia - - - - 2-3 - - - - 5-6 - - 6-7 - - - - - - 31-86
Thrombocytopenia - - - - 4 - - - - - - - - - - - - - - - - 1-2
Metabolic
Hypertransaminasemia 18-20 3-6 2-12 0-6 - - - - - - - - - - 0 1-8 0-2
Neurological
Alteration to CNS and PNS - - - - 4 1 - - - - - - - - - - - - - - - -
Paresthesia - - - - - - - - - - - - - - - - 11 0 - - - -
Neuropathy - - - - - - - - 3 1 5 1 - - - - - - - -
Neuromotor - - - - - - - - - - - - - - - - - - - - 12-15 1-4
Neurosensory - - - - - - - - - - - - - - - - - - - - 16-18 20-37
Whole body
Fatigue - - - - 6 - - - - - - - - - - 25-60 4-19 29 5
Pain 16 - - 10 - - - - - - - - - - 12 2 - - - -
Asthenia 8 1 6-7 0-2 9 2 8-13 1-2     19-41 11-28
Anxiety - - - - - - - - - - - - - - - - 18 4 - - - -
Insomnia - - - - - - - - - - - - - - - - 10 2 - - - -
Weight loss - - - - 1 - - - - - - - - - - 12 0 - - - -
Dehydration - - - - - - - - 5 5 2 2 3 3-4 - - - -
Pulmonary                       16-20 20-37
Dyspnea - - - - - - - - - - - - - - - - 17 4 - - - -
Cough - - - - - - - - - - - - - - - - 16 0 - - - -
Pneumonitis or
pulmonary infiltrates
- - - - - - - - - - - - - - - - 3 <1 - - - -
Musculoskeletal
Arthralgia - - - - - - - - - - - - - - - - 14 0 - - - -
Ocular                 27 1      
Conjunctivitis - - - - 1.3 - - 5-6 0-1 1-5 0-1 - - - - - - - -
Infection - - - - - - - - - - - - - - - - 32 2 16-25 5-14
Cardiac - - - - - - - - - - - - - - - - - - - - 7-12 2-4

a Cells show single value if only one study contributed data, and a range if more than one study contributed data.

b Data on erlotinib are from Perez-Soler, et al. (2004)31, Shepherd, et al. (2005)25, and Jackman, et al. (2005)21

c Chemotherapy studies include studies of docetaxel 75 mg32-34 and 100 mg;33,34 venlafaxine or ifosfamide;34 and pemetrexed.32

Abbreviations: CNS = central nervous system; Gr = grade; PNS = peripheral nervous system

Return to Document

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care